Effects of Gadolinium Contrast Agents in Naive and Nephrectomized Rats: Relevance to Nephrogenic Systemic Fibrosis

被引:41
作者
Grant, D. [1 ]
Johnsen, H. [1 ]
Juelsrud, A. [1 ]
Lovhaug, D. [1 ]
机构
[1] GE Healthcare, Med Diagnost, N-0401 Oslo, Norway
关键词
Animal models; contrast agents; intravenous; gadolinium; kidney; MR imaging; nephrogenic systemic fibrosis; Omniscan; pathology; safety; soft tissue; skin; GADODIAMIDE INJECTION; PHARMACOKINETICS; DERMOPATHY; COMPLEXES; TOXICITY; CHLORIDE; DESIGN;
D O I
10.1080/02841850802637808
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
100231 [临床病理学]; 100902 [航空航天医学];
摘要
Background: Human nephrogenic systemic fibrosis (NSF) is a rare condition reported in patients with severe renal insufficiency exposed to a gadolinium (Gd)-based contrast agent. An animal model of NSF could help to investigate its mechanisms and lead to prevention and treatment. Purpose: To evaluate a possible animal model of NSF using naive and partially nephrectomized rats to induce conditions similar to those in patients at risk of NSF. Material and Methods: Naive rats received intravenous doses of 5 or 10 mmol/kg Omniscan; 5 mmol/kg Magnevist; 1 mmol/kg caldiamide; 1, 2.5, or 5 mmol/kg gadodiamide; 25 mol/kg GdCl3; or 25 mol/kg Gd citrate. Partially nephrectomized rats received 5 mmol/kg Omniscan; 5 mmol/kg Magnevist; 1 mmol/kg caldiamide; 1 mmol/kg gadodiamide; 25 mol/kg GdCl3; or 25 mol/kg Gd citrate. There were three or four animals per group. Clinical signs were recorded during treatment. At termination, clinical biochemistry, histopathology, and tissue Gd and Zn concentrations were investigated. Results: Similar responses to treatment were seen in naive and nephrectomized rats. High doses of gadodiamide were toxic, necessitating early termination of the affected animals. Skin lesions appeared in naive and nephrectomized groups treated with gadodiamide or Omniscan, coinciding with the onset of signs of pruritus, i.e., intensive scratching. The histomorphological features of the skin lesions were also consistent with superficial physical trauma. Dermal fibrosis was not a feature of these skin lesions in any of the groups, i.e., no increased collagen density, CD34+ cells, or increased fibroblasts. This was supported by skinfold measurements that demonstrated no increased skin thickness. Treatment with the gadolinium-based contrast agents and Gd salts resulted in increased Gd content of several tissues. The Gd salts were mainly taken up by the liver and spleen, possibly reflecting formation of insoluble particles and macrophage uptake. Zn tissue concentrations were normal or increased. Other major treatment-related changes included increased serum rat C-reactive protein and histamine; mineralization affecting the dermis, stomach, and blood vessels; and renal proximal tubule vacuolation. Conclusion: The visible skin lesions seen in this study appeared to be caused by excessive scratching in response to pruritus. As there was no evidence of dermal fibrosis, the cardinal feature of human NSF, this did not appear to be a model of human NSF.
引用
收藏
页码:156 / 169
页数:14
相关论文
共 23 条
[1]
Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned [J].
Broome, Dale R. ;
Girguis, Mark S. ;
Baron, Pedro W. ;
Cottrell, Alfred C. ;
Kjellin, Ingrid ;
Kirk, Gerald A. .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 188 (02) :586-592
[2]
THE RELATIONSHIP BETWEEN THERMODYNAMICS AND THE TOXICITY OF GADOLINIUM COMPLEXES [J].
CACHERIS, WP ;
QUAY, SC ;
ROCKLAGE, SM .
MAGNETIC RESONANCE IMAGING, 1990, 8 (04) :467-481
[3]
Carson FL., 1997, HISTOTECHNOLOGY SELF, VSecond
[4]
MAGNETIC-RESONANCE-IMAGING CONTRAST AGENTS - DESIGN AND PHYSICOCHEMICAL PROPERTIES OF GADODIAMIDE [J].
CHANG, CA .
INVESTIGATIVE RADIOLOGY, 1993, 28 :S21-S27
[5]
Nephrogenic fibrosing dermopathy: the first 6 years [J].
Cowper, SE .
CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (06) :785-790
[6]
COWPER SE, NEPHROGENIC BROSING
[7]
Cowper Shawn E, 2007, Adv Dermatol, V23, P131, DOI 10.1016/j.yadr.2007.07.002
[8]
Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [J].
Grobner, T .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (04) :1104-1108
[9]
Hals PA, 1990, P INT SOC MAGN RES 9, P1199
[10]
PRECLINICAL SAFETY ASSESSMENT AND PHARMACOKINETICS OF GADODIAMIDE INJECTION, A NEW MAGNETIC-RESONANCE-IMAGING CONTRAST AGENT [J].
HARPUR, ES ;
WORAH, D ;
HALS, PA ;
HOLTZ, E ;
FURUHAMA, K ;
NOMURA, H .
INVESTIGATIVE RADIOLOGY, 1993, 28 :S28-S43